SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Verthelyi, D
Right arrow Articles by Klinman, D M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verthelyi, D
Right arrow Articles by Klinman, D M
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

DNAse treatment does not improve the survival of lupus prone (NZB6NZW)F1 mice

D Verthelyi

Retroviral Immunology Section, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892

N Dybdal

Pathology Department; Genentech Inc, South San Francisco, 94080, USA

K A Elias

Cardiovascular Research, Genentech Inc, South San Francisco, 94080, USA

D M Klinman

Retroviral Immunology Section, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892

Objective: To examine the efficacy of deoxyribonuclease I (DNAse) therapy in the (NZB6 NZW)F1 murine model of lupus.

Methods: Lupus-prone female (NZB6NZW)F1 mice were treated daily with 0–15 mg/gof recombinant DNAse for 1–6 months. Parameters including anti-DNA autoantibody production, activation of cytokine secreting cells, kidney function and longevity were monitored.

Results: DNAse treatment selectively reduced the number of B cells secreting anti-dsDNA antibodies for approximately one month. However, neither short-term nor long-term treatment altered cytokine production, delayed the onset or reduced the severity of glomerulonephritis, or prolonged survival.

Conclusion: DNAse treatment initiated before, during, or after the onset of murine lupus did not improve clinical outcome.

Key Words: DNAse • anti-DNA • systemic lupus erythematosus • (NZBxNZW)F1 mice

Lupus, Vol. 7, No. 4, 223-230 (1998)
DOI: 10.1191/096120398678920037
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Atkinson, F. Qiao, H. Song, G. S. Gilkeson, and S. Tomlinson
Low-Dose Targeted Complement Inhibition Protects against Renal Disease and Other Manifestations of Autoimmune Disease in MRL/lpr Mice
J. Immunol., January 15, 2008; 180(2): 1231 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
M.-F. Liu, C.-R. Wang, and L.-L. Fung
Letter to the Editor
Lupus, February 1, 2004; 13(2): 142 - 143.
[PDF]

Home page
 LupusHome page
M Jacob, M Napirei, A Ricken, C Dixkens, and H G Mannherz
Histopathology of lupus-like nephritis in Dnase1-deficient mice in comparison to NZB/W F1 mice
Lupus, August 1, 2002; 11(8): 514 - 527.
[Abstract] [PDF]


Advertisement